[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA39964A - Inhibiteurs du protéasome contenant du bore destinés à être utilisés après une thérapie contre le cancer primaire - Google Patents

Inhibiteurs du protéasome contenant du bore destinés à être utilisés après une thérapie contre le cancer primaire

Info

Publication number
MA39964A
MA39964A MA039964A MA39964A MA39964A MA 39964 A MA39964 A MA 39964A MA 039964 A MA039964 A MA 039964A MA 39964 A MA39964 A MA 39964A MA 39964 A MA39964 A MA 39964A
Authority
MA
Morocco
Prior art keywords
boron
cancer therapy
proteasome inhibitors
primary cancer
containing proteasome
Prior art date
Application number
MA039964A
Other languages
English (en)
Inventor
Neeraj Gupta
Ai-Min Hui
Richard Labotka
Guohui Lui
Karthik Venkatakrishnan
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA39964A publication Critical patent/MA39964A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des procédés ou des régimes posologiques comprenant un inhibiteur du protéasome de formule (i), ou un de ses sels pharmaceutiquement acceptables, pour traiter un cancer, ou éviter la récidive ou la progression d'un cancer; le cycle a, z
MA039964A 2014-05-20 2015-05-19 Inhibiteurs du protéasome contenant du bore destinés à être utilisés après une thérapie contre le cancer primaire MA39964A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462000991P 2014-05-20 2014-05-20
US201462019600P 2014-07-01 2014-07-01
US201462088154P 2014-12-05 2014-12-05

Publications (1)

Publication Number Publication Date
MA39964A true MA39964A (fr) 2015-11-26

Family

ID=54554652

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039964A MA39964A (fr) 2014-05-20 2015-05-19 Inhibiteurs du protéasome contenant du bore destinés à être utilisés après une thérapie contre le cancer primaire

Country Status (21)

Country Link
US (5) US20150335668A1 (fr)
EP (1) EP3145526A1 (fr)
JP (2) JP2017524652A (fr)
KR (2) KR102509950B1 (fr)
CN (1) CN106659761A (fr)
AU (2) AU2015264272A1 (fr)
BR (1) BR112016026774A8 (fr)
CA (1) CA2949517A1 (fr)
CL (1) CL2016002948A1 (fr)
CR (1) CR20160577A (fr)
EA (1) EA201692332A1 (fr)
IL (2) IL249025B (fr)
MA (1) MA39964A (fr)
MX (2) MX2016015267A (fr)
PH (1) PH12016502301A1 (fr)
SG (2) SG11201609259VA (fr)
TN (1) TN2016000492A1 (fr)
TW (1) TWI746422B (fr)
UA (1) UA121389C2 (fr)
UY (1) UY36132A (fr)
WO (1) WO2015179443A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11268154B2 (en) 2015-11-04 2022-03-08 Takeda Pharmaceutical Company Limited Methods for the identification, evaluation and treatment of patients having multiple myeloma
JP2019524780A (ja) * 2016-08-04 2019-09-05 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤及び抗ｃｄ３０抗体の組み合わせ
CA3047894A1 (fr) * 2016-12-28 2018-07-05 Daiichi Sankyo Company, Limited Medicament therapeutique pour le syndrome d'alport
US11414437B2 (en) 2017-07-28 2022-08-16 Chengdu Origin Biotechnology Limited Company Borate compound, and synthesis method therefor and uses thereof
EP4444726A1 (fr) * 2021-12-06 2024-10-16 Pretzel Therapeutics, Inc. Inhibiteurs de lonp1, utilisations et méthodes

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2160413A (en) 1935-04-16 1939-05-30 Schering Ag Polyiodo derivatives of acylamino acids and their salts and a method of making the same
NZ203706A (en) 1982-04-22 1986-03-14 Squibb & Sons Inc Occlusive multi-layer wound dressing and hydrocolloidal granules for wound treatment
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
JPS6233170A (ja) 1985-08-07 1987-02-13 Tokuyama Soda Co Ltd 環状ポリエ−テル化合物
JPH0813759B2 (ja) 1986-09-01 1996-02-14 富士写真フイルム株式会社 アルコキシベンゼン誘導体の製造方法
JP2512303B2 (ja) 1987-03-20 1996-07-03 呉羽化学工業株式会社 ２−オキサゾリン−４，５−ジオンのフエニルヒドラゾン誘導体
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5250720A (en) 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
US5242904A (en) 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (fr) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Inhibiteurs de la rénine
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US5159060A (en) 1988-05-27 1992-10-27 Mayo Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
DE3827340A1 (de) 1988-08-12 1990-02-15 Hoechst Ag Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen
MX9206628A (es) 1991-11-22 1993-05-01 Boehringer Ingelheim Pharma Ester de prolinaboronato y metodo para su preparacion.
US5442100A (en) 1992-08-14 1995-08-15 The Procter & Gamble Company β-aminoalkyl and β-N-peptidylaminoalkyl boronic acids
ATE149563T1 (de) 1992-08-14 1997-03-15 Procter & Gamble Alpha-aminoborsäurehaltige flüssige waschmittel
US5492900A (en) 1993-09-10 1996-02-20 Neutron Technology Corporation Method for enhancing the solubility of the boron delivery drug, boronophenylalanine (BPA)
US5935944A (en) 1993-09-10 1999-08-10 Neutron Technology Corporation Formulation for I.V. administration of the boron delivery drug, boronophenylalanine (BPA)
US6060462A (en) 1993-10-20 2000-05-09 Dupont Pharmaceuticals Company Electrophilic peptide analogs as inhibitors of trypsin-like enzymes
FR2712602B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
US5574017A (en) 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5614649A (en) 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
US5834487A (en) 1996-09-24 1998-11-10 Cv Therapeutics Inhibition of 26S and 20S proteasome by indanones
WO1998035691A1 (fr) 1997-02-15 1998-08-20 Proscript, Inc. Traitement d'infarctus par inhibition de nf-kappab
JP2001517631A (ja) 1997-09-25 2001-10-09 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症疾患および自己免疫疾患を治療するためのプロテアソーム阻害剤、ユビキチン経路阻害剤、またはユビキチンプロテアソーム経路を介したＮＦ−κＢの活性化に干渉する剤
CN1282242A (zh) 1997-12-16 2001-01-31 赛福伦公司 多相催化蛋白酶抑制剂用作抗肿瘤剂
US6075150A (en) 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
WO2000024392A1 (fr) 1998-10-26 2000-05-04 Sumitomo Pharmaceuticals Company, Limited Inhibiteur de la formation de beta-amyloide
US6169076B1 (en) 1999-03-31 2001-01-02 Glcosyn Pharmaceuticals, Inc. P-Boronophenylalanine complexes with fructose and related carbohydrates and polyols
AU5788800A (en) 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Peptide boronic acid inhibitors of hepatitis c virus protease
SE0100714D0 (sv) 2000-07-13 2001-02-28 Ap Biotech Ab Reaction vessel and method for distributing fluid in such a vessel
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
JP2002145848A (ja) 2000-11-10 2002-05-22 Kyorin Pharmaceut Co Ltd アルケニルアミノ酸誘導体及びその製造法
DE60239384D1 (de) 2001-01-25 2011-04-21 Us Of America Represented By The Secretary Dept Of Health And Human Services Formulierungen von borsäure-verbindungen
ATE317850T1 (de) 2001-05-30 2006-03-15 Novartis Pharma Gmbh 2-((n-(2-amino-3-(heteroaryl- oder - aryl)propionyl)aminoacyl)amino)- alkylboronsäurederivate
JPWO2003033507A1 (ja) 2001-10-12 2005-02-03 杏林製薬株式会社 ベンジルマロン酸誘導体およびそれを含有するプロテアソーム阻害薬
JPWO2003033506A1 (ja) 2001-10-12 2005-02-03 杏林製薬株式会社 アミノボラン酸誘導体およびそれを含有するプロテアソーム阻害薬
AU2003219652A1 (en) 2002-01-08 2003-07-30 Eisai Co. Ltd. Eponemycin and epoxomicin analogs and uses thereof
AU2003223930A1 (en) 2002-06-14 2003-12-31 Novo Nordisk A/S Pharmaceutical use of boronic acids and esters thereof
US20060084592A1 (en) 2002-09-09 2006-04-20 Trigen Limited Peptide boronic acid inhibitors
TW200418791A (en) 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
GB0405267D0 (en) 2004-03-09 2004-04-21 Trigen Ltd Compounds
SI3385267T1 (sl) 2004-03-30 2022-04-29 Millennium Pharmaceuticals, Inc. Sinteza spojin borovega estra in kisline
DK2030981T3 (da) 2004-05-10 2014-10-13 Onyx Therapeutics Inc Forbindelser til proteasom-enzymhæmning
TW200618820A (en) 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
AU2006242446A1 (en) 2005-04-29 2006-11-09 Kosan Biosciences Incorporated Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either in combination with a proteasome inhibitor
EP1898899A4 (fr) 2005-07-05 2009-07-29 Tufts College Inhibiteurs de proteine alpha d'activation des fibroblastes
JP2009524681A (ja) 2006-01-27 2009-07-02 フェノミックス コーポレーション Ｃ型肝炎ウイルスセリンプロテアーゼインヒビターおよびそのための使用
CL2007002499A1 (es) 2006-08-30 2008-03-14 Phenomix Corp Sales citrato y tartrato de compuestos derivados de acido pirrolidinilaminoacetilpirrolidinboronico, inhibidores de dpp-iv; metodo de preparacion; forma solida; combinacion farmaceutica, util para el tratamiento de diabetes.
WO2009006473A2 (fr) 2007-07-05 2009-01-08 Trustees Of Tufts College Inhibiteurs promedicaments doux de proteasome polypeptidique et methodes d'utilisation associees
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
KR20140042932A (ko) 2007-08-06 2014-04-07 밀레니엄 파머슈티컬스 인코퍼레이티드 프로테아좀 억제제
DK2730581T3 (en) * 2008-06-17 2016-08-15 Millennium Pharm Inc Boronate Ester Compounds and Pharmaceutical Compositions thereof.
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
EP2552216B1 (fr) 2010-03-31 2018-01-24 Millennium Pharmaceuticals, Inc. Dérivés d'acide 1-amino-2-cyclopropyléthylboronique

Also Published As

Publication number Publication date
US11241448B2 (en) 2022-02-08
US20210177871A1 (en) 2021-06-17
MX2021009044A (es) 2021-09-21
CN106659761A (zh) 2017-05-10
TWI746422B (zh) 2021-11-21
US20190125773A1 (en) 2019-05-02
BR112016026774A8 (pt) 2021-07-13
CL2016002948A1 (es) 2017-03-31
CR20160577A (es) 2017-01-06
PH12016502301A1 (en) 2017-02-13
KR102481856B1 (ko) 2022-12-26
BR112016026774A2 (pt) 2017-08-15
JP2017524652A (ja) 2017-08-31
TN2016000492A1 (en) 2018-04-04
UY36132A (es) 2015-11-30
AU2021200370B2 (en) 2022-11-03
WO2015179443A1 (fr) 2015-11-26
US20200171061A1 (en) 2020-06-04
UA121389C2 (uk) 2020-05-25
SG10202003693RA (en) 2020-05-28
AU2015264272A1 (en) 2016-11-24
EP3145526A1 (fr) 2017-03-29
JP6906564B2 (ja) 2021-07-21
KR20220097553A (ko) 2022-07-07
IL274042A (en) 2020-06-30
IL249025A0 (en) 2017-01-31
CA2949517A1 (fr) 2015-11-26
JP2019147837A (ja) 2019-09-05
TW201613570A (en) 2016-04-16
IL249025B (en) 2020-05-31
SG11201609259VA (en) 2016-12-29
US20150335668A1 (en) 2015-11-26
NZ725948A (en) 2024-01-26
AU2021200370A1 (en) 2021-03-18
MX2016015267A (es) 2017-02-22
EA201692332A1 (ru) 2017-04-28
US20190343851A1 (en) 2019-11-14
KR102509950B1 (ko) 2023-03-14
KR20170005042A (ko) 2017-01-11

Similar Documents

Publication Publication Date Title
MX2019002303A (es) Inhibidores de procesos metabolicos celulares.
NZ725778A (en) Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
HK1258779A1 (zh) 用於治療癌症的作為btk抑制劑的吡唑並嘧啶衍生物
MX2023006257A (es) Inhibidores de smyd.
MD4659B1 (ro) Polimorf al inhibitorilor SYK
MX2017009449A (es) Inhibidor jak.
EA201692480A1 (ru) Фармацевтическая композиция
MA40171A (fr) Dérivés d&#39;azamophinan et leur utilisation
MX2017008386A (es) Administración específica del sitio de un inhibidor de btk.
MA40170A (fr) Dérivés hétérocycliques de morphinan et leur utilisation
MX2021009044A (es) Inhibidores de proteasoma que contienen boro para usarse despues de una terapia de cancer primaria.
PH12019501022A1 (en) Pyrazolopyrimidine compounds and methods of use thereof
MX2019012938A (es) Uso del inhibidor mejorador de homologo zeste 2 (ezh2) combinado con el inhibidor tirosina cinasa de bruton (btk) en la preparacion de farmacos para tratar tumores.
MX2018001992A (es) Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa.
PH12019500368A1 (en) Inhibitors of cellular metabolic processes
NZ725948B2 (en) Boron-containing proteasome inhibitors for use after primary cancer therapy
SV2016005317A (es) Derivados de pirrolidina -2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1
TN2014000307A1 (en) Novel morpholinyl derivatives useful as mogat-2 inhibitors